The European Consumers’ Organisation (BEUC) is concerned about an option that the European Commission may include in its review of the EU pharmaceutical strategy: transferable exclusivity vouchers.
In order to encourage the production of medicines with societal benefits, but for which the envisaged market is limited (such as new generation antibiotics), the impact assessment would indicate, according to BEUC, that the Commission is considering offering transferable exclusivity vouchers to...